Enveric Biosciences, Inc. — FY2022 Form 10-K
Reporting period: Year ended December 31, 2022. Filed March 31, 2023. This is an annual report, not a quarterly filing.
Business context
Enveric is a pre-revenue biotechnology company developing small-molecule therapeutics, with its principal focus shifting toward psychedelic-inspired treatments for mental health conditions. Its lead candidate, EB-373, is a psilocin prodrug in preclinical development for anxiety. The company also has an early-stage cannabinoid pipeline, which it planned to transfer to majority-owned Akos Biosciences in a proposed spin-off.
Key financial metrics
| Metric | FY2022 / December 31, 2022 | FY2021 / December 31, 2021 |
|---|---|---|
| Revenue | $0; no revenue generated to date | $0 |
| Operating expenses | $27.4 million | $64.6 million |
| Research and development expense | $8.0 million | $4.8 million |
| Net loss | $18.5 million; $18.8 million attributable to shareholders | $49.0 million |
| Net loss per share, basic and diluted | $13.00 | $103.69 |
| Operating cash flow | $(17.1) million | $(11.5) million |
| Cash | $17.7 million | $17.4 million |
| Working capital | $14.4 million | Not clearly provided in the supplied text |
| Total assets | $19.6 million | $26.7 million |
| Total liabilities | $4.0 million | $4.4 million |
Gross margin is not applicable because the company reported no revenue. The filing reports no conventional borrowings; liabilities primarily include accrued amounts, lease obligations, warrant and investment-option liabilities, and a derivative liability. Cash provided by financing was $18.2 million, while investing activities used $0.6 million. Enveric raised approximately $18.2 million through equity-related financings, warrant exercises and the Akos investment.
Changes versus the prior year
- Operating expenses fell 58%, chiefly because 2021 included much higher stock-based compensation and MagicMed transaction-related legal costs, as well as $38.7 million of impairment charges. FY2022 operating expenses included $7.5 million of impairment charges.
- R&D expense rose 68% to $8.0 million, reflecting expanded psychedelic research and a full year of MagicMed-related activity.
- Net loss narrowed to $18.5 million from $49.0 million. The comparison is substantially affected by non-cash impairment charges and fair-value changes in warrant and investment-option liabilities; it does not indicate operating profitability.
- Operating cash use increased to $17.1 million from $11.5 million. Financing inflows supported cash balances despite that use.
- The company recorded $6.0 million of intangible-asset impairment and $1.5 million of goodwill impairment in 2022. Goodwill and indefinite-lived intangible assets were reduced to zero at year-end.
Outlook, risks and unusual items
- Going concern: The auditor’s report and management identify substantial doubt about Enveric’s ability to continue as a going concern. Management said cash was expected to support anticipated outlays through December 31, 2023, but not beyond, and that additional financing or cost reductions would be needed. The financial statements contain no adjustments for the outcome of this uncertainty.
- Liquidity disclosure: The balance sheet and MD&A report positive working capital of $14.4 million, while the auditor’s explanatory paragraph refers to a “significant working capital deficiency.” Investors should reconcile this apparent inconsistency in the full filing.
- Development outlook: In a March 2023 announcement, the company said it expected to begin a Phase 1, dose-ascending safety and tolerability study of EB-373 in Australia in Q4 2023. The CRO contract was approximately AUD 3.0 million (about $1.5 million at the contract date). This is a stated plan, not a guarantee or financial earnings forecast.
- Akos spin-off and contingent exposure: Completion depended on conditions including Akos qualifying for Nasdaq listing. Enveric guaranteed the investor’s put right on Akos preferred shares if the spin-off did not occur by May 5, 2023, or was abandoned; the stated value was $1.0 million plus accrued unpaid dividends. The investor had funded $1.0 million, with up to $4.0 million additional investment tied to the spin-off.
- Financing and dilution: 2022 financings included a February offering with approximately $9.1 million net proceeds and July registered-direct and PIPE offerings with approximately $7.1 million net proceeds. The July transactions also issued 1.07 million investment options, and existing warrants were repriced. A 1-for-50 reverse stock split took effect in July 2022. Further capital may be difficult to obtain and could dilute shareholders.
- Accounting and controls: Management concluded internal control over financial reporting and disclosure controls were ineffective at year-end due to material weaknesses, including inadequate segregation of duties and deficient control documentation and monitoring. Remediation was underway but not complete.
- Principal business risks: Candidates remain preclinical, with no approved products or product revenue; development, clinical, regulatory and funding outcomes are uncertain. Psychedelic compounds are controlled substances in many jurisdictions, and regulatory, safety, intellectual-property, competition, staffing, inflation and execution risks could delay or prevent development.
- Other notable items: The company’s share price declined approximately 96% during 2022. It regained Nasdaq minimum-bid-price compliance in July 2022. Management noted that cash balances at financial institutions could exceed insured limits, although it reported no accounts at Silicon Valley Bank or Signature Bank.
Most important facts for investors to verify
- Current cash, burn rate, financing plans and runway following the filing date; the stated runway only extended through December 31, 2023.
- The status and terms of the Akos spin-off, the investor’s put right and Enveric’s related guarantee.
- EB-373’s subsequent regulatory and clinical progress, trial start and costs, and any resulting changes to the development timeline.
- Whether internal-control material weaknesses were remediated and whether subsequent filings identify further deficiencies.
- The fully diluted share count and potential dilution from outstanding warrants, investment options, equity awards and future financings.
- The discrepancy between reported positive working capital and the auditor’s reference to a working capital deficiency, along with the assumptions behind the substantial-doubt conclusion.